Triple combinationtherapy brings lasting improvement in cysticfibrosis, shows study
Recent studies demonstrated that the triple combination CFTR modulator therapy elexacaftor/tezacaftor/ivacaftor improves lung function and reduces pulmonary exacerbations in CF patients with at least oneabnormal viscoelastic properties of airway mucus, chronic airway infection and inflammation have not been studied.
Conflict of interest: Kerstin Fentker reports support for the present manuscript in the form of a PhD stipend paidConflict of interest: Jobst Röhmel reports payment for presentations among educational events from Vertex Pharmaceuticals, outside the submitted work.
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Inflammation associated with lung function abnormalities in COVID-19 survivors - BMC Pulmonary MedicineBackground Activation of inflammatory pathways promotes organ dysfunction in COVID-19. Currently, there are reports describing lung function abnormalities in COVID-19 survivors; however, the biological mechanisms remain unknown. The aim of this study was to analyze the association between serum biomarkers collected during and following hospitalization and pulmonary function in COVID-19 survivors. Methods Patients recovering from severe COVID-19 were prospectively evaluated. Serum biomarkers were analyzed from admission to hospital, peak during hospitalization, and at the time of discharge. Pulmonary function was measured approximately 6 weeks after discharge. Results 100 patients (63% male) were included (age 48 years, SD ± 14) with 85% having at least one comorbidity. Patients with a restrictive spirometry pattern (n = 46) had greater inflammatory biomarkers compared to those with normal spirometry (n = 54) including peak Neutrophil-to-Lymphocyte ratio (NLR) value [9.3 (10.1) vs. 6.5 (6.6), median (IQR), p = 0.027] and NLR at hospital discharge [4.6 (2.9) vs. 3.2 (2.9) p = 0.005] and baseline C-reactive protein value [164.0 (147.0) vs. 106.5 (139.0) mg/dL, p = 0.083). Patients with an abnormal diffusing capacity (n = 35) had increased peak NLR [8.9 (5.9) vs. 5.6 (5.7) mg/L, p = 0.029]; baseline NLR [10.0 (19.0) vs. 4.0 (3.0) pg/ml, p = 0.002] and peak Troponin-T [10.0 (20.0) vs. 5.0 (5.0) pg/ml, p = 0.011] compared to patients with normal diffusing capacity (n = 42). Multivariable linear regression analysis identified predictors of restrictive spirometry and low diffusing capacity, but only accounted for a low degree of variance in pulmonary function outcome. Conclusion Overexpression of inflammatory biomarkers is associated with subsequent lung function abnormalities in patients recovered from severe COVID-19.
Read more »
Muckamore Abbey Hospital set to shut in June 2024The planned hospital closure will have no bearing on the criminal investigation into patient abuse nor the work of the Muckamore public inquiry, says Department of Health:
Read more »
Concerns over neighbours’ privacy halts decision on homes developmentOne local councillor said: 'I am concerned that the way these properties will be overlooked is not acceptable'
Read more »
Residents fear new housing estate will be built 'just 1m from their properties''My concerns are that the gable end of the new house could be just one metre from our border. And it could be a family house with four bedrooms and three bathrooms, taking up a of of light'
Read more »
F1 2024 calendar conclusions: Cash is king as teams reach possible boiling pointLogistical challenges, staff pressure and a higher workload than ever are all side-effects of the F1 2024 calendar.
Read more »